Besides the recent breakthrough in KRAS targeting drugs that a newly developed AMG510 has been showing great response in KRAS G12C positive lung and colorectal cancer [14–16], indicating its future potential use in pancreatic cancer, only numbered molecular drugs including olaparib and PARP inhibitors were approved by FDA for PAAD patients with BRCA mutation [17–20]. Here, KRAS is linked to familial pancreatic carcinoma.